These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21380780)

  • 21. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
    Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
    J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
    Law LY
    J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
    [No Abstract]   [Full Text] [Related]  

  • 23. Abiraterone in metastatic salivary duct carcinoma.
    Urban D; Rischin D; Angel C; D'Costa I; Solomon B
    J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
    De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
    Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
    J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel].
    Ogino T; Komoike Y; Ishitobi M; Motomura K; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2234-6. PubMed ID: 19106581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
    Sonke GS; Mandjes IA; Holtkamp MJ; Schot M; van Werkhoven E; Wesseling J; Vrancken Peeters MJ; Rodenhuis S; Linn SC
    Breast J; 2013; 19(4):419-26. PubMed ID: 23682812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
    Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
    Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
    Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
    Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
    Sharon E; Kelly RJ; Szabo E
    Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
    Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
    J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature.
    Derouane F; Yombi JC; Baurain JF; Danse E; Komuta M; Yildiz H
    Acta Clin Belg; 2020 Aug; 75(4):301-307. PubMed ID: 31035903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological therapy of salivary duct carcinoma.
    Nashed M; Casasola RJ
    J Laryngol Otol; 2009 Feb; 123(2):250-2. PubMed ID: 18405406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
    Lin NU; Guo H; Yap JT; Mayer IA; Falkson CI; Hobday TJ; Dees EC; Richardson AL; Nanda R; Rimawi MF; Ryabin N; Najita JS; Barry WT; Arteaga CL; Wolff AC; Krop IE; Winer EP; Van den Abbeele AD
    J Clin Oncol; 2015 Aug; 33(24):2623-31. PubMed ID: 26169615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.